--- schema_version: "secwatch.filing_event.v1" accession: "0001213900-23-051702" form_type: "8-K" ticker: "UNCY" cik: "0001766140" company_name: "Unicycive Therapeutics, Inc." filed_at: "2023-06-26T23:59:59+00:00" generated_at: "2026-06-13T17:11:37.908300+00:00" event_type: "other" sentiment: "neutral" materiality_score: 0.2 calibrated_materiality_score: 0.2 confidence: "high" source: SEC EDGAR --- # Unicycive shareholders elect all 4 director nominees, approve reverse stock split and equity plan amendment ## Summary - Directors elected: Dr. Shalabh Gupta, Dr. Sandeep Laumas, Dr. John Ryan, Dr. Gaurav Aggarwal. - Ratified Mayer Hoffman McCann as auditor for FY2023 (13,057,585 for, 30,776 against). - Approved Nasdaq 20% issuance proposal (8,129,197 for, 236,958 against). - Approved reverse stock split proposal (12,679,613 for, 412,810 against). - Approved amendment and restatement of 2021 Omnibus Equity Incentive Plan (9,474,374 for, 959,587 against). ## SEC filing metadata - accession: 0001213900-23-051702 - form_type: 8-K - ticker: UNCY - cik: 0001766140 - company_name: Unicycive Therapeutics, Inc. - filed_at: 2023-06-26T23:59:59+00:00 - event_type: other - sentiment: neutral - materiality_score: 0.2 - calibrated_materiality_score: 0.2 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390023051702/0001213900-23-051702-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390023051702/ea180941-8k_unicycive.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001213900-23-051702 - JSON: https://secwatch.observer/filing/0001213900-23-051702.json - Plain text: https://secwatch.observer/filing/0001213900-23-051702.txt ## Key facts - Shareholder Votes Unicycive Therapeutics, Inc. shareholders approved Election of four nominees for director to serve until the 2024 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death. at the 2023-06-26 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-26 source text: Proposal 1 . All of the four (4) nominees for director were elected to serve until the 2024 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the four (4) directors was as follows: Directors For Withhold Abstain Broker Non Vote Dr. Shalabh Gupta 10,308,931 0 135,675 2,655,662 Dr. Sandeep Laumas 9,453,731 0 990,876 2,655,661 Dr. John Ryan 9,298,925 0 1,145,681 2,655,662 Dr. Gaurav Aggarwal 10,307,961 0 136,646 2,655,661 evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023051702/0001213900-23-051702-index.htm - Shareholder Votes Unicycive Therapeutics, Inc. shareholders approved Reverse Stock Split Proposal at the 2023-06-26 meeting. - Proposal: reverse split - Outcome: passed - Meeting: 2023-06-26 source text: Proposal 4. The Reverse Stock Split Proposal was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 12,679,613 412,810 7,840 3 evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023051702/0001213900-23-051702-index.htm - Shareholder Votes Unicycive Therapeutics, Inc. shareholders approved Nasdaq 20% Issuance Proposal at the 2023-06-26 meeting. - Outcome: passed - Meeting: 2023-06-26 source text: Proposal 3. The Nasdaq 20% Issuance Proposal was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 8,129,197 236,958 11,705 2,655,661 evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023051702/0001213900-23-051702-index.htm - Shareholder Votes Unicycive Therapeutics, Inc. shareholders approved Amendment and restatement of the 2021 Omnibus Equity Incentive Plan at the 2023-06-26 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2023-06-26 source text: Proposal 5. The amendment and restatement of the 2021 Omnibus Equity Incentive Plan was approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 9,474,374 959,587 10,645 2,655,662 evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023051702/0001213900-23-051702-index.htm - Shareholder Votes Unicycive Therapeutics, Inc. shareholders approved Ratification of appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm for fiscal year ending December 31, 2023. at the 2023-06-26 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-26 source text: Proposal 2. The appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2023 was ratified and approved by the stockholders by the votes set forth in the table below: For Against Abstain Broker Non Vote 13,057,585 30,776 11,904 1 evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023051702/0001213900-23-051702-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.